Malaysia

Malaysia operates a dual regulatory framework under the Ministry of Health (MOH). Medical devices, including diagnostics and certain digital health tools classified as medical devices, are regulated by the Medical Device Authority (MDA) under the Medical Device Act 2012 (Act 737) and its accompanying regulations. Pharmaceuticals and biological products fall under the jurisdiction of the National Pharmaceutical Regulatory Agency (NPRA), governed by the Control of Drugs and Cosmetics Regulations 1984 under the Sale of Drugs Act 1952. Both agencies require formal product registration prior to market entry, with risk-based classification systems determining the depth of technical review required. Digital health products are subject to evolving guidance, and the MDA has issued advisories to clarify when software and AI-driven tools meet the definition of a medical device requiring registration.

Applicants must appoint a locally registered company or authorized representative to submit and hold product registrations in Malaysia. For medical devices, submissions follow MDA-prescribed formats aligned with the ASEAN Medical Device Directive (AMDD) and the Global Harmonization Task Force (GHTF) framework. Pharmaceutical submissions are accepted in ACTD (ASEAN Common Technical Dossier) or ICH CTD format, with NPRA increasingly recognizing approvals from reference agencies such as the US FDA, EMA, Health Canada, TGA (Australia), and PMDA (Japan) to facilitate expedited review pathways. Malaysia participates in the ASEAN Medical Device Product Working Group and broader ASEAN regulatory harmonization initiatives, with ongoing reforms aimed at reducing duplication and accelerating market access timelines for innovative and priority health products.

Public sector procurement in Malaysia is centralized primarily through the MOH, with the Pharmaceutical Services Programme (PSP) managing the national formulary and coordinating tenders for medicines and health products for government facilities. Large-scale federal procurement is conducted via the Ministry of Finance-linked procurement portal (MyProcurement) and the MOH's own panel and contract system. The National Pharmaceutical Management Unit (UPFN) under MOH oversees medicine supply chain management and formulary listing decisions, which are prerequisites for public tender participation. State health departments may conduct supplementary procurement for non-centralized items, though the majority of high-value and high-volume health products are managed at the federal level. Inclusion on the Malaysian Drug Formulary (MDF) or the Medical Device Formulary is typically required before products can be procured for public facilities.

The private healthcare sector in Malaysia is substantial and commercially driven, with procurement decisions made at the hospital group, clinic chain, or individual facility level, governed by internal formulary committees and purchasing departments. Major private hospital groups such as IHH Healthcare, KPJ Healthcare, and Ramsay Sime Darby represent significant commercial channels and negotiate directly with manufacturers or distributors. Malaysia is an upper-middle-income country and does not typically access large-scale donor procurement mechanisms such as UNICEF Supply Division, Global Fund, or Gavi as a recipient; however, MOH has historically collaborated with these agencies for specific program-level initiatives and surveillance activities. The government maintains a preference for locally manufactured or locally assembled products through price preference policies and Bumiputera procurement quotas under certain tender categories, and the MOH has expressed strategic interest in developing domestic pharmaceutical and medical device manufacturing capacity aligned with the National Pharmaceutical Industry Blueprint.